Medical Cannabis for Veterans: What Research Says About Sleep, Pain, and Emotional Distress
Last Updated: February 2026 | Reading Time: 5 minutes
Among Canadian veterans who use medicinal cannabis, three conditions dominate: chronic pain, disrupted sleep, and emotional distress. These three frequently co-occur — PTSD and chronic pain share high comorbidity rates in veteran populations, and sleep disruption is a hallmark symptom of both. This article reviews what peer-reviewed research has found about medical cannabis and each of these domains in Canadian and international veteran populations.
Sleep: The Strongest Signal in the Research
Of the three areas reviewed here, sleep shows the most consistent findings. The 2023 study by Nacasch, Avni & Toren, published in Frontiers in Psychiatry, followed 14 treatment-resistant combat veteran patients for whom standard pharmacological and psychotherapy interventions had not produced adequate results. Following medical cannabis use, researchers documented significant improvements in total sleep score, subjective sleep quality, and sleep duration (p<0.01), alongside significant improvements in total PTSD severity and the intrusiveness, avoidance, and alertness subdomains (p<0.05). Nightmare frequency did not significantly improve (p=0.27).
Sleep disruption in veterans is not incidental; it is central to the constellation of symptoms associated with PTSD, chronic pain, and the neurological effects of combat exposure. Improving sleep quality has downstream effects on pain tolerance, emotional regulation, and functional capacity. The Nacasch findings, while limited by cohort size and the absence of a control group, are notable because they observed measurable improvements in a population that had not responded to prior treatment.
The 2019 Canadian authorized patient survey by Lucas, Baron & Jikomes (Harm Reduction Journal, N=2,032) found that insomnia was among the most common conditions reported by authorized patients, alongside chronic pain, PTSD, and anxiety.
Chronic Pain: What Authorized Canadian Patients Report
The Lucas et al. (2019) survey found that 83.7% of authorized Canadian patients reported pain and mental health conditions as primary, when chronic pain, arthritis, headache, mental health conditions, PTSD, and insomnia are grouped together. A 2023 qualitative study by Storey, Keeler-Villa, Harris, Anthonypillai, Tippin, Parihar & Rash (Canadian Journal of Pain) found that veterans in focus groups described medicinal cannabis use primarily for chronic pain — often alongside sleep disturbance and emotional distress, rather than in isolation.
What these findings collectively illustrate is that chronic pain does not present alone in this population. Veterans managing pain are typically also managing sleep disruption, emotional symptoms, or both. Cannabis authorization for one condition in this group, therefore, frequently addresses a cluster rather than a single complaint.
Emotional Distress: What the Research Does and Does Not Say
The evidence on emotional distress is more nuanced than the evidence on sleep and pain, and honest communication requires precision about what the research shows.
The Storey, Keeler-Villa, Harris, Anthonypillai, Tippin, Parihar & Rash (2023) study found that veterans in focus groups reported using medicinal cannabis for emotional distress, alongside pain and sleep concerns. This is patient-reported use, not a clinical outcome measure. The researchers documented what veterans say they are experiencing and what they are using cannabis for — not a controlled trial result establishing efficacy for emotional symptoms.
A 2025 study by Sheehy et al. (Journal of Veterans Studies) noted a recurring pattern in the prior literature: recreational cannabis use was associated with worsening PTSD-related outcomes in some studies, while medicinal use was associated with improved outcomes. Sheehy et al.’s own cross-sectional data did not find cannabis use characteristics significantly associated with PTSD severity, and the overall literature remains equivocal.
The defensible position is that authorized medical cannabis is associated with patient-reported reduction in emotional distress in some studies, that this effect appears more consistent under medicinal than recreational conditions in the prior literature, and that controlled trial data specifically targeting emotional distress as a primary outcome remain limited.
The Co-Occurring Condition Picture
What the research collectively points to is not a single-condition use case. Veterans accessing medical cannabis for sleep are typically also managing pain. Veterans reporting emotional distress relief are often the same patients for whom pain and sleep improvements have been documented. The conditions are not cleanly separable, and the evidence base reflects that complexity.
For a veteran managing chronic pain acquired through service, disrupted sleep from PTSD, and ongoing emotional distress — all common in the post-service population — medical authorization through a licensed producer represents a regulated pathway to a consistent supply, with coverage through Veterans Affairs Canada for eligible patients.
Access for Canadian Veterans
VAC covers medical cannabis costs for eligible veterans through Medavie Blue Cross direct billing. RCMP members, Canadian Armed Forces personnel, and those covered under the Interim Federal Health Program have parallel coverage pathways. A prescription from a qualified healthcare provider is required.
This article summarizes published peer-reviewed research for informational purposes. It does not constitute medical advice. Medical cannabis requires authorization from a qualified healthcare provider. The research cited represents the findings of independent investigators and does not constitute a health claim about any specific product.
References
- Lucas, Baron & Jikomes (2019). Harm Reduction Journal, 16(1): 9. DOI: 10.1186/s12954-019-0278-6
- Nacasch, Avni & Toren (2023). Frontiers in Psychiatry, 13: 1014630. DOI: 10.3389/fpsyt.2022.1014630
- Sheehy, Storey, Rash, Tippin, Parihar & Harris (2025). Journal of Veterans Studies, 11(1): 30–46. DOI: 10.21061/jvs.v11i1.582
- Storey, Keeler-Villa, Harris, Anthonypillai, Tippin, Parihar & Rash (2023). Canadian Journal of Pain, 7(1): 2232838. DOI: 10.1080/24740527.2023.2232838